期刊
CANCER TREATMENT REVIEWS
卷 73, 期 -, 页码 84-90出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2019.01.005
关键词
Prostate cancer; Oligometastatic; Radiotherapy; De novo; Oligorecurrent; Oligoprogressive
类别
资金
- Swiss Prostate Cancer Award from the Movember Foundation
Oligometastatic prostate cancer represents an intermediate state between a localized tumor and widespread metastatic disease. Its specific clinical features suggest the existence of a distinct biology which still needs to be elucidated. New imaging techniques like prostate specific membrane antigen (PSMA) PET scans have shown to perform well in the staging and restaging of this category of patients, at different phases of disease evolution. Despite limited prospective evidence, metastasis-directed therapies (MDT) are emerging as valid treatment options able to postpone systemic therapies and probably improve survival outcome. The aim of this review is to shed light on the clinical scenario of prostate cancer patients with limited metastatic disease burden and highlight the role of MDT strategies in this setting.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据